EarningsAstraZeneca reported total revenues of $13.565 billion, beating consensus by 4%.
GuidanceThe company raised its 2024 guidance, expecting higher growth in total revenue and core EPS.
Market PerformanceStrong fundamentals such as low IP risks, active label expansion, and a diverse pipeline with near-term catalysts suggest AZN's value is not fully reflected in its share price.